Abstract
The primary goal in reopening an infarct-related artery is the restoration of myocardial tissue-level perfusion. In a variable proportion of patients with ST-elevation myocardial infarction, however, microcirculatory impairment may persist after epicardial coronary artery recanalization. This phenomenon is known as microvascular obstruction (MVO). Ischemic injury, reperfusion injury, and distal embolization along with the individual response to each of these mechanisms are variably involved in the pathogenesis of MVO in the single patient. Importantly, MVO is associated with a worse prognosis both at short- and long-term follow-up. MVO can be assessed in the cath-lab by simple angiographic indexes, such as Thrombolysis in Myocardial Infarction grade score and Myocardial Blush Grade, or by invasive measures of coronary flow pattern. Imaging techniques, such as myocardial contrast echocardiography or cardiac magnetic resonance, and ST-segment resolution on standard electrocardiogram are used in the days following reperfusion with the patient in the coronary care unit. In this article, we review the available data regarding pathogenesis, diagnosis and the prognostic significance of MVO after primary percurtaneous coronary intervention in ST-elevation myocardial infarction patients, with a brief highlighting on the crucial role of its prevention and its early detection.
Keywords: ST-elevation myocardial infarction, primary percutaneous coronary intervention, microvascular obstruction, pathogenesis, diagnosis, prognosis
Current Vascular Pharmacology
Title:Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Volume: 11 Issue: 2
Author(s): Giampaolo Niccoli, Nicola Cosentino, Silvia Minelli, Leonardo Cataneo and Filippo Crea
Affiliation:
Keywords: ST-elevation myocardial infarction, primary percutaneous coronary intervention, microvascular obstruction, pathogenesis, diagnosis, prognosis
Abstract: The primary goal in reopening an infarct-related artery is the restoration of myocardial tissue-level perfusion. In a variable proportion of patients with ST-elevation myocardial infarction, however, microcirculatory impairment may persist after epicardial coronary artery recanalization. This phenomenon is known as microvascular obstruction (MVO). Ischemic injury, reperfusion injury, and distal embolization along with the individual response to each of these mechanisms are variably involved in the pathogenesis of MVO in the single patient. Importantly, MVO is associated with a worse prognosis both at short- and long-term follow-up. MVO can be assessed in the cath-lab by simple angiographic indexes, such as Thrombolysis in Myocardial Infarction grade score and Myocardial Blush Grade, or by invasive measures of coronary flow pattern. Imaging techniques, such as myocardial contrast echocardiography or cardiac magnetic resonance, and ST-segment resolution on standard electrocardiogram are used in the days following reperfusion with the patient in the coronary care unit. In this article, we review the available data regarding pathogenesis, diagnosis and the prognostic significance of MVO after primary percurtaneous coronary intervention in ST-elevation myocardial infarction patients, with a brief highlighting on the crucial role of its prevention and its early detection.
Export Options
About this article
Cite this article as:
Niccoli Giampaolo, Cosentino Nicola, Minelli Silvia, Cataneo Leonardo and Crea Filippo, Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance, Current Vascular Pharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570161111311020013
DOI https://dx.doi.org/10.2174/1570161111311020013 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Attenuation of Cardiac Ischaemia-reperfusion Injury by Treatment with Hydrogen-rich Water
Current Molecular Medicine Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Ligands: Novel Pharmacological Agents in the Treatment of Ischemia Reperfusion Injury
Current Molecular Medicine Heme Oxygenase-1 against Vascular Insufficiency: Roles of Atherosclerotic Disorders
Current Pharmaceutical Design Physiology and Pathophysiology of Na+/H+ Exchange Isoform 1 in the Central Nervous System
Current Neurovascular Research Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry Receptor for Advanced Glycation Endproducts (RAGE): A Formidable Force in the Pathogenesis of the Cardiovascular Complications of Diabetes & Aging
Current Molecular Medicine Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets The Sirtuin Inhibitor Nicotinamide Enhances Neuronal Cell Survival During Acute Anoxic Injury Through AKT, BAD, PARP, and Mitochondrial Associated "Anti-Apoptotic" Pathways
Current Neurovascular Research STAT-1 and STAT-3: Closely Related Transcription Factors with Antagonistic Effects on Cell Proliferation and Apoptosis
Current Genomics Cells and Mediators of Inflammation in Acute Pancreatitis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Hydrogen Sulfide in Inflammation: Friend or Foe?
Inflammation & Allergy - Drug Targets (Discontinued) Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Current Topics in Medicinal Chemistry Drug Metabolism and Pharmacokinetics of Dammarane Triterpenoids
Current Drug Metabolism Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology